{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:42:01Z","timestamp":1788892921765,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108549","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:53:16Z","timestamp":1745002396000},"page":"108549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["EGFR mutation testing across the osimertinib clinical program"],"prefix":"10.1016","volume":"204","author":[{"given":"Marie Laure","family":"Murat-Onana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-5109","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-559X","authenticated-orcid":false,"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Rukazenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-0523","authenticated-orcid":false,"given":"Manana","family":"Javey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Li-Sucholeiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2025.108549_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108549_b0010","article-title":"Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Med (Bal)"},{"issue":"14","key":"10.1016\/j.lungcan.2025.108549_b0015","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108549_b0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: A meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.pathol.2020.03.003","article-title":"Prevalence of the EGFR T790M and other resistance mutations in the Australian population and histopathological correlation in a small subset of cases","volume":"52","author":"Kim","year":"2020","journal-title":"Pathology"},{"issue":"12a","key":"10.1016\/j.lungcan.2025.108549_b0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/imj.12587","article-title":"High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer","volume":"44","author":"Stone","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.lungcan.2025.108549_b0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2022.12.010","article-title":"Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy","volume":"181","author":"Hondelink","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108549_b0045","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/1759-7714.12651","article-title":"EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China","volume":"9","author":"Pi","year":"2018","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108549_b0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108549_b0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.lungcan.2025.108549_b0065","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1200\/JCO-24-02133","article-title":"Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2024.2","volume":"42","author":"Bazhenova","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108549_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated","volume":"382","author":"Ramalingam","year":"2020","journal-title":"EGFR-Mutated Advanced NSCLC, N Engl J Med"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108549_b0075","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: An update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108549_b0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO Guideline rapid recommendation update","volume":"40","author":"Pisters","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.lungcan.2025.108549_b0095","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2025.108549_b0100","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.3.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 20, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108549_b0105","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108549_b0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108549_b0115","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108549_b0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108549_b0125","doi-asserted-by":"crossref","first-page":"e0202865","DOI":"10.1371\/journal.pone.0202865","article-title":"Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108549_b0130","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/cancers15215130","article-title":"Diagnostic workup, treatment patterns, and clinical outcomes in early-stage IB-IIIA non-small-cell lung cancer patients in Denmark","volume":"15","author":"Uldbjerg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108549_b0135","article-title":"EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study","volume":"38","author":"Helland","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108549_b0140","article-title":"EGFR testing patterns and detection of EGFR exon 20 insertions in the United States","volume":"3","author":"Lin","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lungcan.2025.108549_b0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.lungcan.2025.108549_b0150","first-page":"191","article-title":"Real-world practice patterns for patients with advanced non-small cell lung cancer: Multicenter retrospective cohort study in Japan","volume":"8","author":"Isobe","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108549_b0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15078","article-title":"Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: Statement from a working group of thoracic pathologists","volume":"84","author":"Kerr","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2025.108549_b0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2022.08.003","article-title":"Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement","volume":"172","author":"Navani","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108549_b0165","unstructured":"U.S. Food and Drug Administration, Premarket approval (PMA) P150044, cobas EGFR Mutation Test v2, 2016, 2016. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P150044. (Accessed April 5, 2024)."},{"key":"10.1016\/j.lungcan.2025.108549_b0170","unstructured":"U.S. Food and Drug Administration, Supplement S018 to premarket approval (PMA) P120019, cobas EGFR Mutation Test v2, 2018. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P120019S018. (Accessed April 5, 2024)."},{"key":"10.1016\/j.lungcan.2025.108549_b0175","unstructured":"U.S. Food and Drug Administration, Premarket approval (PMA) P120019, cobas EGFR Mutation Test v2, 2015. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P120019S007. (Accessed April 5, 2024)."},{"key":"10.1016\/j.lungcan.2025.108549_b0180","unstructured":"Roche, cobas\u00ae EGFR Mutation Test v2, 2016. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150047C.pdf. (Accessed January 5, 2024)."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108549_b0185","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108549_b0190","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non\u2013small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108549_b0195","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cllc.2023.02.002","article-title":"Adjuvant osimertinib vs. placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: ADAURA2","volume":"24","author":"Tsutani","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"31","key":"10.1016\/j.lungcan.2025.108549_b0205","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089518","article-title":"Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC trial","volume":"9","author":"Benlloch","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108549_b0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/jclinpath-2012-201240","article-title":"Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer","volume":"66","author":"Lopez-Rios","year":"2013","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cncy.21513","article-title":"Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer","volume":"123","author":"Lozano","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.lungcan.2025.108549_b0230","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"10048","key":"10.1016\/j.lungcan.2025.108549_b0235","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(16)31340-X","article-title":"Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease","volume":"388","author":"Hiley","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108549_b0240","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1038\/s41598-022-10288-8","article-title":"Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC","volume":"12","author":"Koyama","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.lungcan.2025.108549_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.07.007","article-title":"Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study","volume":"101","author":"Nosaki","year":"2016","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108549_b0250","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/cancers14061563","article-title":"Diagnostic yield of transbronchial cryobiopsy guided by radial endobronchial ultrasound and fluoroscopy in the radiologically suspected lung cancer: A single institution prospective study","volume":"14","author":"Ankudavicius","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108549_b0255","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108549_b0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000519380","article-title":"Concordance of cytological specimens with histological tissue for detection of epidermal growth factor receptor mutation in non-small cell lung cancer: A systematic review","volume":"66","author":"Chua","year":"2022","journal-title":"Acta Cytol"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108549_b0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41467-024-55456-8","article-title":"Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling","volume":"16","author":"Kim","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108549_b0275","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cncy.22085","article-title":"The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective","volume":"127","author":"Young","year":"2019","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108549_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101628","article-title":"Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe","volume":"8","author":"Hofman","year":"2023","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108549_b0285","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s12325-022-02189-z","article-title":"Real-world patient characteristics, treatment patterns, and mutation testing patterns among US patients with advanced non-small cell lung cancer harboring EGFR mutations","volume":"39","author":"He","year":"2022","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108549_b0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.lungcan.2025.108549_b0295","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3390\/cancers13235879","article-title":"The impact of core tissues on successful next-generation sequencing analysis of specimens obtained through endobronchial ultrasound-guided transbronchial needle aspiration","volume":"13","author":"Uchimura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108549_b0300","unstructured":"FoundationOne\u00aeCDx, Specimen instructions, 2021. https:\/\/www.foundationmedicine.com\/sites\/default\/files\/media\/documents\/2023-10\/F1CDx_Specimen_Instructions%20%283%29.pdf. (Accessed April 5, 2024)."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0305","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: A literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108549_b0310","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/cas.13511","article-title":"Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples","volume":"109","author":"Kiura","year":"2018","journal-title":"Cancer Sci"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:21:20Z","timestamp":1753993280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"alternative-id":["S0169500225004416"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108549","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR mutation testing across the osimertinib clinical program","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108549"}}